# Teva autoimmune antibody notches ph. 2 win in celiac disease

> **Newsylist Open Intelligence Dossier** · First detected: 2026-09-03 07:29 UTC · Category: Business · Sources: 9 · Current Velocity: 6.75

## Intelligence Brief
"Teva autoimmune antibody notches ph. 2 win in celiac disease" developed substantial multi-source reporting across the Business sector, tracked across 9 distinct newsrooms by Newsylist.


Key reporting was led by Endpoints News, finance.yahoo.com, FirstWord Pharma and Reuters. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.


Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.

## Verified Facts & Key Claims
### What drove coverage for Teva autoimmune antibody notches ph. 2 win in celiac disease?
Coverage spiked when 9 independent newsrooms published 9 verified reports during this coverage cycle.

### How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Endpoints News | Teva reports a single-shot success in celiac disease, heating the IL-15 market | 2026-09-02 14:52 | [Source Link](https://news.google.com/rss/articles/CBMiiwFBVV95cUxNMDlmQzB0S1FMcTQwUERyTGlxZTFjeHNPUGZHLXBtU29xOW9va3ZRcVQ2Q1V5LXpvRGNHaE9kVE5ZbERTcUlHdUZiV2h4ejR5cm92ZGdPQ0l0LS1ERXdrX1hUY3lyOHM3MFVmZjg3QnlOb1BUOHp0NHgya2NyVGNYbEF1RnRpWnJoQk1J?oc=5) |
| finance.yahoo.com | Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study | 2026-09-02 14:52 | [Source Link](https://news.google.com/rss/articles/CBMiigFBVV95cUxNQmp0UDFMNUR0UlAwazRVVGQxQ3JWWktrM200TlpBalJHNHgyZDVySHJZS2tOcFRSQUdtS0d5QjlpY1F1RzFtbnNKWTFIOG9aNERLZlVVYmdtUlAzZ1Rqc3lxQTdfUFFNS1lOM05jSi1wbnRxdWZ5YWUxS3o1aG9pM2gtc3NramJMZEE?oc=5) |
| FirstWord Pharma | Teva's anti–IL-15 shows positive mid-stage results in coeliac disease | 2026-09-02 14:52 | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE5FUGJWRTFoa2xRTDNZaURCcmNadzhFenhoX3NXZUhRNTZCOFp6SV8xSjhJZWhmcmxsSDJjdmR0Yzhzd09jWXlPNC1RUmplRFA2ajJB?oc=5) |
| Reuters | Teva's immune disorder drug meets main goal in mid-stage trial | 2026-09-02 14:52 | [Source Link](https://news.google.com/rss/articles/CBMiygFBVV95cUxOcVFEcmljY2dUX2Nob3I4bE1XdTlBblBuRU8ta0NVbTNNYjg3T0U0QmlnWGhJc3ZtQi1RejgtSko0QXNPTUhEWV9zYUlqSEJ2alV3LVZCX3BvaFA2MWZjYTNCSFEwWXhEUGpUclE1RHB4VGNtYWl0ekpISmVYenBTbTdyb1dnR2o1Q2RxS29adGVHa05NT0tWak1JNk12aE9QVTFidXIyMFRpUmZPM1ZaVDlSZDRXWHNVRS1Hc3VJREFwTUJKaFB6d2Zn?oc=5) |
| tradingview.com | Teva's immune disorder drug meets main goal in mid-stage trial | 2026-09-02 14:52 | [Source Link](https://news.google.com/rss/articles/CBMizAFBVV95cUxORWF6R0ZqRmNMaXc1Q04yZVczUEpLY0t1dWlLdU5IRU1zWk1JYzVzcXVXVWRPRmVNbmVTNW1QT3hvdjdCM2UtSFc3ODNZVHBRMGhGQkFDOWpYb0pxTUtNSkJyVFpXd1Bub1VSWFpEay1SMUF5eEkyUmx0UnV1dkJPcENRLUlsYkpBUWpmbXhRVFlmVXVudnhVR0JBMUVwQjdDM3hsd3ZYN3ZaSWdhM2VnTDRfQVZESUdDMTd5UWFpVU40ck5oRUlwaEtZRVo?oc=5) |
| Yahoo Finance | Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute | 2026-09-02 14:52 | [Source Link](https://news.google.com/rss/articles/CBMimAFBVV95cUxQRWFUY0VBbkp4UDU3WmpKWUY1eEgxaEg4LVQ2U3kzTnBDZVIwLVhYSW5NYUd2WlVGeXBfY2tveVh5VDg4cTZTV0ZNQ0FZeUdUVFdhLWh2OWVYdEpJNXZSZGd2V0tpNDhQMlJjMHpFWE84dlV3UmVxcEd4NTAzbVpFS2p0bkNtNmF2QkY2QUpDVzJ1S2RvdXIwbg?oc=5) |
| Investing.com India | Why is Teva Pharma stock surging today? | 2026-09-02 14:52 | [Source Link](https://news.google.com/rss/articles/CBMioAFBVV95cUxNUDVmNDRnWjFvcThTS3VnRl9FeGJDblZ0RXgyUVhqWmczY2Y5UkhiNTVqaThhQmdEYV9MZURUTEp6M2pudjI2RXZ2T1RTQnoxeTd1bHhyNjIwZ1lUZDYxSGV6V2tGeTdGSjZsZnQ0OTAyVFQ2SEo0UGtsRDhjdXVnTktEaFFTeWNzSkd6YTJhS3luNVpER0dod2x0ZFNhbThl?oc=5) |
| WKZO | Teva’s immune disorder drug meets main goal in mid-stage trial | 2026-09-02 14:52 | [Source Link](https://news.google.com/rss/articles/CBMilAFBVV95cUxQU2hMN2k5MG9zMFJpeW5wQ2JmdXdlMTFpc0F4d0pteGZ5czdjUEptQ0xFWDN6R1hmeGxjMFR1dUVCUFU3Ni1aRXRlbHdOTWwzRkhrYWkwc29aMVN4ajVnZmEtdU1HQU8ySU5Qd24xSFo4UmRhY2FuamFIOE01TVVreVRicHR2N1pJMS1qNTJ6dDNrczZ6?oc=5) |
| Fierce Biotech | Teva autoimmune antibody notches ph. 2 win in celiac disease | 2026-09-02 14:52 | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxNVWhQU3l4RGJJOUVKUEQ2QWQ0SGt1YVZyVnVOUUc4eDlvVlF0c1hNeFVVbTRSNjVJN1AwcU9wTmpFWFg1S0t3d1VqZWkwNmhGUGMwQlNnSHpiTzh1XzFaM2daRWItV3VIdmxYM2ZPaUNtZFBNTWw2UFc2aFZuaGJ4ZERBbnZ1MS1ZUGEzRWxjaExvQTh4RUdrOHZR?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-09-03/teva-autoimmune-antibody-notches-ph-2-win-in-celiac-disease*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*